Link Professor Kiyotaka Hitomi vistits Zedira

Link Zedira keeps pricing stable for 2026!

Link Successful ISO9001:2015 recertification

Link Zedira supports the Tampere Celiac Disease Symposium 2025

Link Co-authored article published in Nature Immunology: Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease

Link Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira

Link Discover Our New Catalogue Edition and Dive into the World of Transglutaminases!

Link Co-authored article: The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment

Link Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

Link Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie

Link Co-authored posters at ICDS 2022

Link Successful ISO9001:2015 recertification

Link Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)

Link Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

Link Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease

Link Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease

Link Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie

Link Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

Link Enzymatic Crosslinking of Gelatin: How Andracon® MTG Enables Tunable, Physiologically Compatible Hydrogels

Link Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis

Link Transglutaminase antibodies and neurological manifestations of gluten sensitivity

Link DZG Aktuell: Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227

Link Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible?

Link Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Link Tridegin as FXIIIa inhibitor

Link Microbial transglutaminase: from discovery to market

Link Tissue transglutaminase inhibitors

Link Tissue transglutaminase in Alzheimers Disease

Link Factor XIIIa: novel target for anticoagulation?

Link Microbial transglutaminase for site-specific protein conjugation

Link Transglutaminases: current research and applications - future directions

World ADC 2026

Date: 12.10.2026 - 15.10.2026
Location: San Diego, USA

21st International Celiac Disease Symposium 2026

Date: 17.11.2026 - 20.11.2026
Location: Melbourne, Australia